nodes	percent_of_prediction	percent_of_DWPC	metapath
Midazolam—CYP2E1—Dacarbazine—skin cancer	0.101	0.16	CbGbCtD
Midazolam—ABCB1—Vismodegib—skin cancer	0.0844	0.134	CbGbCtD
Midazolam—CYP3A4—Temozolomide—skin cancer	0.073	0.115	CbGbCtD
Midazolam—CYP3A4—Imiquimod—skin cancer	0.073	0.115	CbGbCtD
Midazolam—CYP3A4—Vismodegib—skin cancer	0.0506	0.08	CbGbCtD
Midazolam—CYP3A7—Docetaxel—skin cancer	0.0469	0.0742	CbGbCtD
Midazolam—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0469	0.0742	CbGbCtD
Midazolam—ABCB1—Dactinomycin—skin cancer	0.0444	0.0702	CbGbCtD
Midazolam—CYP3A4—Vemurafenib—skin cancer	0.04	0.0633	CbGbCtD
Midazolam—CYP3A5—Docetaxel—skin cancer	0.0352	0.0557	CbGbCtD
Midazolam—ABCB1—Docetaxel—skin cancer	0.0229	0.0362	CbGbCtD
Midazolam—CYP3A4—Docetaxel—skin cancer	0.0137	0.0217	CbGbCtD
Midazolam—GABRR3—nerve—skin cancer	0.00818	0.0876	CbGeAlD
Midazolam—GABRQ—nerve—skin cancer	0.00818	0.0876	CbGeAlD
Midazolam—GABRR2—nerve—skin cancer	0.00709	0.076	CbGeAlD
Midazolam—GABRR1—nerve—skin cancer	0.00683	0.0731	CbGeAlD
Midazolam—GABRE—hair follicle—skin cancer	0.00317	0.034	CbGeAlD
Midazolam—CYP4B1—mammalian vulva—skin cancer	0.00292	0.0313	CbGeAlD
Midazolam—GABRA3—neck—skin cancer	0.00288	0.0309	CbGeAlD
Midazolam—GABRP—nipple—skin cancer	0.00282	0.0302	CbGeAlD
Midazolam—CYP4B1—female reproductive system—skin cancer	0.0025	0.0268	CbGeAlD
Midazolam—GABRE—nipple—skin cancer	0.00215	0.023	CbGeAlD
Midazolam—CYP4B1—head—skin cancer	0.00209	0.0224	CbGeAlD
Midazolam—GABRQ—head—skin cancer	0.00194	0.0208	CbGeAlD
Midazolam—GABRR3—head—skin cancer	0.00194	0.0208	CbGeAlD
Midazolam—GABRG3—head—skin cancer	0.0017	0.0182	CbGeAlD
Midazolam—GABRR2—head—skin cancer	0.00168	0.018	CbGeAlD
Midazolam—GABRA4—mammalian vulva—skin cancer	0.00166	0.0177	CbGeAlD
Midazolam—Tenderness—Fluorouracil—skin cancer	0.00164	0.00598	CcSEcCtD
Midazolam—GABRR1—head—skin cancer	0.00162	0.0173	CbGeAlD
Midazolam—Respiratory failure—Temozolomide—skin cancer	0.00158	0.00577	CcSEcCtD
Midazolam—Phlebitis—Bleomycin—skin cancer	0.00155	0.00566	CcSEcCtD
Midazolam—Dyspepsia—Vismodegib—skin cancer	0.00155	0.00563	CcSEcCtD
Midazolam—Redness—Docetaxel—skin cancer	0.00153	0.00558	CcSEcCtD
Midazolam—Gastrointestinal disorder—Vismodegib—skin cancer	0.00152	0.00552	CcSEcCtD
Midazolam—Fatigue—Vismodegib—skin cancer	0.00151	0.00552	CcSEcCtD
Midazolam—Dysarthria—Fluorouracil—skin cancer	0.00151	0.00552	CcSEcCtD
Midazolam—Pain—Vismodegib—skin cancer	0.0015	0.00547	CcSEcCtD
Midazolam—Constipation—Vismodegib—skin cancer	0.0015	0.00547	CcSEcCtD
Midazolam—Depressed level of consciousness—Temozolomide—skin cancer	0.0015	0.00547	CcSEcCtD
Midazolam—Connective tissue disorder—Vemurafenib—skin cancer	0.0015	0.00547	CcSEcCtD
Midazolam—Disorientation—Bleomycin—skin cancer	0.00149	0.00545	CcSEcCtD
Midazolam—Skin exfoliation—Temozolomide—skin cancer	0.00148	0.00541	CcSEcCtD
Midazolam—CYP4B1—lymph node—skin cancer	0.00146	0.0157	CbGeAlD
Midazolam—Injury—Bleomycin—skin cancer	0.00145	0.0053	CcSEcCtD
Midazolam—Phlebitis—Dactinomycin—skin cancer	0.00145	0.00527	CcSEcCtD
Midazolam—Depression—Imiquimod—skin cancer	0.00145	0.00527	CcSEcCtD
Midazolam—Eye disorder—Vemurafenib—skin cancer	0.00143	0.0052	CcSEcCtD
Midazolam—Neuropathy peripheral—Imiquimod—skin cancer	0.00142	0.00518	CcSEcCtD
Midazolam—Cardiac disorder—Vemurafenib—skin cancer	0.00142	0.00516	CcSEcCtD
Midazolam—GABRP—female reproductive system—skin cancer	0.00141	0.0151	CbGeAlD
Midazolam—GABRD—head—skin cancer	0.00141	0.0151	CbGeAlD
Midazolam—Mediastinal disorder—Vemurafenib—skin cancer	0.00138	0.00501	CcSEcCtD
Midazolam—Chills—Vemurafenib—skin cancer	0.00137	0.00499	CcSEcCtD
Midazolam—GABRG1—head—skin cancer	0.00135	0.0145	CbGeAlD
Midazolam—GABRA6—head—skin cancer	0.00135	0.0144	CbGeAlD
Midazolam—Erythema—Vemurafenib—skin cancer	0.00133	0.00484	CcSEcCtD
Midazolam—GABRB1—head—skin cancer	0.00131	0.0141	CbGeAlD
Midazolam—GABRA5—head—skin cancer	0.00131	0.014	CbGeAlD
Midazolam—Thrombophlebitis—Temozolomide—skin cancer	0.0013	0.00475	CcSEcCtD
Midazolam—GABRB3—connective tissue—skin cancer	0.00129	0.0138	CbGeAlD
Midazolam—Connective tissue disorder—Imiquimod—skin cancer	0.00128	0.00466	CcSEcCtD
Midazolam—Rhinorrhoea—Docetaxel—skin cancer	0.00128	0.00465	CcSEcCtD
Midazolam—Lethargy—Dactinomycin—skin cancer	0.00127	0.00464	CcSEcCtD
Midazolam—Asthenia—Vismodegib—skin cancer	0.00126	0.00459	CcSEcCtD
Midazolam—GABRE—mammalian vulva—skin cancer	0.00126	0.0134	CbGeAlD
Midazolam—Visual impairment—Imiquimod—skin cancer	0.00125	0.00457	CcSEcCtD
Midazolam—Pruritus—Vismodegib—skin cancer	0.00124	0.00453	CcSEcCtD
Midazolam—Euphoric mood—Fluorouracil—skin cancer	0.00123	0.00448	CcSEcCtD
Midazolam—Eye disorder—Imiquimod—skin cancer	0.00122	0.00443	CcSEcCtD
Midazolam—GABRA3—head—skin cancer	0.00122	0.013	CbGeAlD
Midazolam—Thrombophlebitis—Fluorouracil—skin cancer	0.0012	0.00437	CcSEcCtD
Midazolam—GABRA4—head—skin cancer	0.00119	0.0127	CbGeAlD
Midazolam—Swelling—Fluorouracil—skin cancer	0.00118	0.00429	CcSEcCtD
Midazolam—GABRR2—lymph node—skin cancer	0.00118	0.0126	CbGeAlD
Midazolam—GABRP—head—skin cancer	0.00118	0.0126	CbGeAlD
Midazolam—Immune system disorder—Imiquimod—skin cancer	0.00118	0.00429	CcSEcCtD
Midazolam—Mediastinal disorder—Imiquimod—skin cancer	0.00117	0.00428	CcSEcCtD
Midazolam—Chills—Imiquimod—skin cancer	0.00117	0.00426	CcSEcCtD
Midazolam—Disorientation—Fluorouracil—skin cancer	0.00116	0.00423	CcSEcCtD
Midazolam—Cough—Vemurafenib—skin cancer	0.00116	0.00423	CcSEcCtD
Midazolam—Mental disorder—Imiquimod—skin cancer	0.00114	0.00416	CcSEcCtD
Midazolam—Bronchospasm—Bleomycin—skin cancer	0.00114	0.00414	CcSEcCtD
Midazolam—Erythema—Imiquimod—skin cancer	0.00113	0.00413	CcSEcCtD
Midazolam—Diplopia—Temozolomide—skin cancer	0.00113	0.00411	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00112	0.00409	CcSEcCtD
Midazolam—Vomiting—Vismodegib—skin cancer	0.00112	0.00407	CcSEcCtD
Midazolam—Affect lability—Temozolomide—skin cancer	0.00111	0.00405	CcSEcCtD
Midazolam—Rash—Vismodegib—skin cancer	0.00111	0.00403	CcSEcCtD
Midazolam—Dermatitis—Vismodegib—skin cancer	0.00111	0.00403	CcSEcCtD
Midazolam—Anaphylactic shock—Vemurafenib—skin cancer	0.00108	0.00395	CcSEcCtD
Midazolam—GABRE—female reproductive system—skin cancer	0.00108	0.0115	CbGeAlD
Midazolam—Mood swings—Temozolomide—skin cancer	0.00107	0.00389	CcSEcCtD
Midazolam—Cardiac failure—Fluorouracil—skin cancer	0.00106	0.00388	CcSEcCtD
Midazolam—Nervous system disorder—Vemurafenib—skin cancer	0.00106	0.00388	CcSEcCtD
Midazolam—Ataxia—Temozolomide—skin cancer	0.00106	0.00386	CcSEcCtD
Midazolam—Lethargy—Fluorouracil—skin cancer	0.00106	0.00386	CcSEcCtD
Midazolam—Skin disorder—Vemurafenib—skin cancer	0.00105	0.00384	CcSEcCtD
Midazolam—Respiratory failure—Docetaxel—skin cancer	0.00105	0.00383	CcSEcCtD
Midazolam—Nausea—Vismodegib—skin cancer	0.00104	0.0038	CcSEcCtD
Midazolam—Agitation—Imiquimod—skin cancer	0.00104	0.0038	CcSEcCtD
Midazolam—Osteoarthritis—Fluorouracil—skin cancer	0.00104	0.00379	CcSEcCtD
Midazolam—Syncope—Imiquimod—skin cancer	0.00102	0.0037	CcSEcCtD
Midazolam—Hypotension—Vemurafenib—skin cancer	0.00101	0.00369	CcSEcCtD
Midazolam—Muscular weakness—Temozolomide—skin cancer	0.000995	0.00363	CcSEcCtD
Midazolam—Irritability—Fluorouracil—skin cancer	0.000992	0.00361	CcSEcCtD
Midazolam—GABRG2—head—skin cancer	0.000991	0.0106	CbGeAlD
Midazolam—GABRB2—head—skin cancer	0.000991	0.0106	CbGeAlD
Midazolam—Cough—Imiquimod—skin cancer	0.000989	0.0036	CcSEcCtD
Midazolam—Cardiac arrest—Fluorouracil—skin cancer	0.000988	0.0036	CcSEcCtD
Midazolam—Skin exfoliation—Docetaxel—skin cancer	0.000987	0.00359	CcSEcCtD
Midazolam—Ataxia—Fluorouracil—skin cancer	0.000977	0.00356	CcSEcCtD
Midazolam—Anxiety—Imiquimod—skin cancer	0.000962	0.0035	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000958	0.00349	CcSEcCtD
Midazolam—Dry mouth—Imiquimod—skin cancer	0.000944	0.00344	CcSEcCtD
Midazolam—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000937	0.00341	CcSEcCtD
Midazolam—Fatigue—Vemurafenib—skin cancer	0.000935	0.00341	CcSEcCtD
Midazolam—Nasopharyngitis—Fluorouracil—skin cancer	0.000929	0.00339	CcSEcCtD
Midazolam—Constipation—Vemurafenib—skin cancer	0.000928	0.00338	CcSEcCtD
Midazolam—Lightheadedness—Docetaxel—skin cancer	0.000925	0.00337	CcSEcCtD
Midazolam—Muscular weakness—Fluorouracil—skin cancer	0.000917	0.00334	CcSEcCtD
Midazolam—ABCB1—blood vessel—skin cancer	0.000913	0.00978	CbGeAlD
Midazolam—GABRB3—female reproductive system—skin cancer	0.000911	0.00976	CbGeAlD
Midazolam—Shock—Imiquimod—skin cancer	0.00091	0.00332	CcSEcCtD
Midazolam—Nervous system disorder—Imiquimod—skin cancer	0.000907	0.00331	CcSEcCtD
Midazolam—GABRA2—head—skin cancer	0.000906	0.0097	CbGeAlD
Midazolam—Tachycardia—Imiquimod—skin cancer	0.000903	0.00329	CcSEcCtD
Midazolam—Skin disorder—Imiquimod—skin cancer	0.000899	0.00327	CcSEcCtD
Midazolam—GABRE—head—skin cancer	0.000898	0.00962	CbGeAlD
Midazolam—GABRA1—head—skin cancer	0.000875	0.00938	CbGeAlD
Midazolam—Phlebitis—Docetaxel—skin cancer	0.000871	0.00317	CcSEcCtD
Midazolam—Depression—Temozolomide—skin cancer	0.000867	0.00316	CcSEcCtD
Midazolam—Thrombophlebitis—Docetaxel—skin cancer	0.000867	0.00316	CcSEcCtD
Midazolam—SLC22A1—head—skin cancer	0.000855	0.00916	CbGeAlD
Midazolam—Neuropathy peripheral—Temozolomide—skin cancer	0.000852	0.0031	CcSEcCtD
Midazolam—Swelling—Docetaxel—skin cancer	0.00085	0.0031	CcSEcCtD
Midazolam—Paraesthesia—Imiquimod—skin cancer	0.000831	0.00303	CcSEcCtD
Midazolam—Chills—Bleomycin—skin cancer	0.00083	0.00302	CcSEcCtD
Midazolam—Dyspnoea—Imiquimod—skin cancer	0.000825	0.00301	CcSEcCtD
Midazolam—Somnolence—Imiquimod—skin cancer	0.000822	0.003	CcSEcCtD
Midazolam—Dyspepsia—Imiquimod—skin cancer	0.000814	0.00297	CcSEcCtD
Midazolam—Erythema—Bleomycin—skin cancer	0.000805	0.00293	CcSEcCtD
Midazolam—Hypersensitivity—Vemurafenib—skin cancer	0.000799	0.00291	CcSEcCtD
Midazolam—Gastrointestinal disorder—Imiquimod—skin cancer	0.000799	0.00291	CcSEcCtD
Midazolam—Fatigue—Imiquimod—skin cancer	0.000798	0.00291	CcSEcCtD
Midazolam—Visual disturbance—Docetaxel—skin cancer	0.000792	0.00288	CcSEcCtD
Midazolam—CYP2B6—skin of body—skin cancer	0.000791	0.00847	CbGeAlD
Midazolam—Pain—Imiquimod—skin cancer	0.000791	0.00288	CcSEcCtD
Midazolam—Neuropathy peripheral—Fluorouracil—skin cancer	0.000785	0.00286	CcSEcCtD
Midazolam—Asthenia—Vemurafenib—skin cancer	0.000778	0.00284	CcSEcCtD
Midazolam—Hallucination—Temozolomide—skin cancer	0.000776	0.00283	CcSEcCtD
Midazolam—Chills—Dactinomycin—skin cancer	0.000774	0.00282	CcSEcCtD
Midazolam—Cardiac failure—Docetaxel—skin cancer	0.000769	0.0028	CcSEcCtD
Midazolam—Pruritus—Vemurafenib—skin cancer	0.000767	0.0028	CcSEcCtD
Midazolam—Connective tissue disorder—Temozolomide—skin cancer	0.000767	0.00279	CcSEcCtD
Midazolam—Lethargy—Docetaxel—skin cancer	0.000765	0.00279	CcSEcCtD
Midazolam—Feeling abnormal—Imiquimod—skin cancer	0.000762	0.00278	CcSEcCtD
Midazolam—GABRB3—head—skin cancer	0.000761	0.00816	CbGeAlD
Midazolam—Visual impairment—Temozolomide—skin cancer	0.000752	0.00274	CcSEcCtD
Midazolam—Erythema—Dactinomycin—skin cancer	0.000751	0.00274	CcSEcCtD
Midazolam—Urticaria—Imiquimod—skin cancer	0.000735	0.00268	CcSEcCtD
Midazolam—Eye disorder—Temozolomide—skin cancer	0.000729	0.00266	CcSEcCtD
Midazolam—Cardiac disorder—Temozolomide—skin cancer	0.000724	0.00264	CcSEcCtD
Midazolam—Dizziness—Vemurafenib—skin cancer	0.000717	0.00261	CcSEcCtD
Midazolam—Ataxia—Docetaxel—skin cancer	0.000705	0.00257	CcSEcCtD
Midazolam—Immune system disorder—Temozolomide—skin cancer	0.000705	0.00257	CcSEcCtD
Midazolam—Mediastinal disorder—Temozolomide—skin cancer	0.000703	0.00256	CcSEcCtD
Midazolam—Cough—Bleomycin—skin cancer	0.000703	0.00256	CcSEcCtD
Midazolam—Chills—Temozolomide—skin cancer	0.0007	0.00255	CcSEcCtD
Midazolam—Vomiting—Vemurafenib—skin cancer	0.00069	0.00251	CcSEcCtD
Midazolam—Rash—Vemurafenib—skin cancer	0.000684	0.00249	CcSEcCtD
Midazolam—Mental disorder—Temozolomide—skin cancer	0.000684	0.00249	CcSEcCtD
Midazolam—Dermatitis—Vemurafenib—skin cancer	0.000683	0.00249	CcSEcCtD
Midazolam—Hypersensitivity—Imiquimod—skin cancer	0.000682	0.00248	CcSEcCtD
Midazolam—Headache—Vemurafenib—skin cancer	0.00068	0.00248	CcSEcCtD
Midazolam—Erythema—Temozolomide—skin cancer	0.000679	0.00248	CcSEcCtD
Midazolam—Nasopharyngitis—Docetaxel—skin cancer	0.000671	0.00244	CcSEcCtD
Midazolam—Asthenia—Imiquimod—skin cancer	0.000664	0.00242	CcSEcCtD
Midazolam—Confusional state—Bleomycin—skin cancer	0.000663	0.00241	CcSEcCtD
Midazolam—Anaphylactic shock—Bleomycin—skin cancer	0.000657	0.00239	CcSEcCtD
Midazolam—Pruritus—Imiquimod—skin cancer	0.000654	0.00238	CcSEcCtD
Midazolam—Nausea—Vemurafenib—skin cancer	0.000644	0.00235	CcSEcCtD
Midazolam—CYP2B6—lymphoid tissue—skin cancer	0.000641	0.00686	CbGeAlD
Midazolam—Vision blurred—Temozolomide—skin cancer	0.00064	0.00233	CcSEcCtD
Midazolam—Bronchospasm—Docetaxel—skin cancer	0.000638	0.00232	CcSEcCtD
Midazolam—Tremor—Temozolomide—skin cancer	0.000636	0.00232	CcSEcCtD
Midazolam—GABRA2—lymph node—skin cancer	0.000634	0.00679	CbGeAlD
Midazolam—GABRE—lymph node—skin cancer	0.000629	0.00674	CbGeAlD
Midazolam—Erythema—Fluorouracil—skin cancer	0.000626	0.00228	CcSEcCtD
Midazolam—Agitation—Temozolomide—skin cancer	0.000624	0.00227	CcSEcCtD
Midazolam—CYP2B6—female reproductive system—skin cancer	0.000618	0.00662	CbGeAlD
Midazolam—Hypotension—Bleomycin—skin cancer	0.000614	0.00224	CcSEcCtD
Midazolam—Dizziness—Imiquimod—skin cancer	0.000612	0.00223	CcSEcCtD
Midazolam—Vertigo—Temozolomide—skin cancer	0.00061	0.00222	CcSEcCtD
Midazolam—CYP2E1—lymphoid tissue—skin cancer	0.000601	0.00644	CbGeAlD
Midazolam—Cough—Temozolomide—skin cancer	0.000593	0.00216	CcSEcCtD
Midazolam—Paraesthesia—Bleomycin—skin cancer	0.00059	0.00215	CcSEcCtD
Midazolam—Vision blurred—Fluorouracil—skin cancer	0.00059	0.00215	CcSEcCtD
Midazolam—Vomiting—Imiquimod—skin cancer	0.000588	0.00214	CcSEcCtD
Midazolam—Dyspnoea—Bleomycin—skin cancer	0.000586	0.00214	CcSEcCtD
Midazolam—Rash—Imiquimod—skin cancer	0.000583	0.00213	CcSEcCtD
Midazolam—Dermatitis—Imiquimod—skin cancer	0.000583	0.00212	CcSEcCtD
Midazolam—CYP2E1—female reproductive system—skin cancer	0.00058	0.00621	CbGeAlD
Midazolam—Headache—Imiquimod—skin cancer	0.00058	0.00211	CcSEcCtD
Midazolam—Anxiety—Temozolomide—skin cancer	0.000576	0.0021	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000574	0.00209	CcSEcCtD
Midazolam—Neuropathy peripheral—Docetaxel—skin cancer	0.000567	0.00206	CcSEcCtD
Midazolam—Dry mouth—Temozolomide—skin cancer	0.000566	0.00206	CcSEcCtD
Midazolam—Pain—Bleomycin—skin cancer	0.000562	0.00205	CcSEcCtD
Midazolam—Confusional state—Temozolomide—skin cancer	0.000559	0.00204	CcSEcCtD
Midazolam—Anaphylactic shock—Temozolomide—skin cancer	0.000554	0.00202	CcSEcCtD
Midazolam—Nausea—Imiquimod—skin cancer	0.000549	0.002	CcSEcCtD
Midazolam—Nervous system disorder—Temozolomide—skin cancer	0.000544	0.00198	CcSEcCtD
Midazolam—Feeling abnormal—Bleomycin—skin cancer	0.000542	0.00197	CcSEcCtD
Midazolam—Skin disorder—Temozolomide—skin cancer	0.000538	0.00196	CcSEcCtD
Midazolam—Fatigue—Dactinomycin—skin cancer	0.000528	0.00193	CcSEcCtD
Midazolam—Pain—Dactinomycin—skin cancer	0.000524	0.00191	CcSEcCtD
Midazolam—Urticaria—Bleomycin—skin cancer	0.000522	0.0019	CcSEcCtD
Midazolam—CYP2B6—head—skin cancer	0.000516	0.00553	CbGeAlD
Midazolam—Confusional state—Fluorouracil—skin cancer	0.000515	0.00188	CcSEcCtD
Midazolam—Anaphylactic shock—Fluorouracil—skin cancer	0.000511	0.00186	CcSEcCtD
Midazolam—Connective tissue disorder—Docetaxel—skin cancer	0.00051	0.00186	CcSEcCtD
Midazolam—Feeling abnormal—Dactinomycin—skin cancer	0.000505	0.00184	CcSEcCtD
Midazolam—Nervous system disorder—Fluorouracil—skin cancer	0.000501	0.00183	CcSEcCtD
Midazolam—Visual impairment—Docetaxel—skin cancer	0.0005	0.00182	CcSEcCtD
Midazolam—Tachycardia—Fluorouracil—skin cancer	0.000499	0.00182	CcSEcCtD
Midazolam—Paraesthesia—Temozolomide—skin cancer	0.000498	0.00181	CcSEcCtD
Midazolam—Dyspnoea—Temozolomide—skin cancer	0.000494	0.0018	CcSEcCtD
Midazolam—Somnolence—Temozolomide—skin cancer	0.000493	0.0018	CcSEcCtD
Midazolam—Dyspepsia—Temozolomide—skin cancer	0.000488	0.00178	CcSEcCtD
Midazolam—Eye disorder—Docetaxel—skin cancer	0.000485	0.00177	CcSEcCtD
Midazolam—CYP2E1—head—skin cancer	0.000484	0.00519	CbGeAlD
Midazolam—Hypersensitivity—Bleomycin—skin cancer	0.000484	0.00176	CcSEcCtD
Midazolam—Cardiac disorder—Docetaxel—skin cancer	0.000482	0.00175	CcSEcCtD
Midazolam—Gastrointestinal disorder—Temozolomide—skin cancer	0.000479	0.00174	CcSEcCtD
Midazolam—Fatigue—Temozolomide—skin cancer	0.000478	0.00174	CcSEcCtD
Midazolam—Hypotension—Fluorouracil—skin cancer	0.000477	0.00174	CcSEcCtD
Midazolam—Pain—Temozolomide—skin cancer	0.000474	0.00173	CcSEcCtD
Midazolam—Constipation—Temozolomide—skin cancer	0.000474	0.00173	CcSEcCtD
Midazolam—Asthenia—Bleomycin—skin cancer	0.000472	0.00172	CcSEcCtD
Midazolam—Immune system disorder—Docetaxel—skin cancer	0.000469	0.00171	CcSEcCtD
Midazolam—Mediastinal disorder—Docetaxel—skin cancer	0.000468	0.0017	CcSEcCtD
Midazolam—CYP3A4—female reproductive system—skin cancer	0.000467	0.005	CbGeAlD
Midazolam—Chills—Docetaxel—skin cancer	0.000466	0.0017	CcSEcCtD
Midazolam—Pruritus—Bleomycin—skin cancer	0.000465	0.00169	CcSEcCtD
Midazolam—Paraesthesia—Fluorouracil—skin cancer	0.000459	0.00167	CcSEcCtD
Midazolam—Feeling abnormal—Temozolomide—skin cancer	0.000457	0.00166	CcSEcCtD
Midazolam—Dyspnoea—Fluorouracil—skin cancer	0.000455	0.00166	CcSEcCtD
Midazolam—Mental disorder—Docetaxel—skin cancer	0.000455	0.00166	CcSEcCtD
Midazolam—Somnolence—Fluorouracil—skin cancer	0.000454	0.00165	CcSEcCtD
Midazolam—Erythema—Docetaxel—skin cancer	0.000452	0.00165	CcSEcCtD
Midazolam—Hypersensitivity—Dactinomycin—skin cancer	0.000452	0.00165	CcSEcCtD
Midazolam—Dyspepsia—Fluorouracil—skin cancer	0.00045	0.00164	CcSEcCtD
Midazolam—ABCB1—epithelium—skin cancer	0.000445	0.00476	CbGeAlD
Midazolam—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000441	0.00161	CcSEcCtD
Midazolam—Urticaria—Temozolomide—skin cancer	0.00044	0.0016	CcSEcCtD
Midazolam—Asthenia—Dactinomycin—skin cancer	0.00044	0.0016	CcSEcCtD
Midazolam—Pain—Fluorouracil—skin cancer	0.000437	0.00159	CcSEcCtD
Midazolam—Feeling abnormal—Fluorouracil—skin cancer	0.000421	0.00153	CcSEcCtD
Midazolam—Vomiting—Bleomycin—skin cancer	0.000418	0.00152	CcSEcCtD
Midazolam—Rash—Bleomycin—skin cancer	0.000414	0.00151	CcSEcCtD
Midazolam—Dermatitis—Bleomycin—skin cancer	0.000414	0.00151	CcSEcCtD
Midazolam—Hypersensitivity—Temozolomide—skin cancer	0.000408	0.00149	CcSEcCtD
Midazolam—Urticaria—Fluorouracil—skin cancer	0.000406	0.00148	CcSEcCtD
Midazolam—Syncope—Docetaxel—skin cancer	0.000405	0.00148	CcSEcCtD
Midazolam—Asthenia—Temozolomide—skin cancer	0.000398	0.00145	CcSEcCtD
Midazolam—Cough—Docetaxel—skin cancer	0.000394	0.00144	CcSEcCtD
Midazolam—Pruritus—Temozolomide—skin cancer	0.000392	0.00143	CcSEcCtD
Midazolam—Nausea—Bleomycin—skin cancer	0.00039	0.00142	CcSEcCtD
Midazolam—Vomiting—Dactinomycin—skin cancer	0.00039	0.00142	CcSEcCtD
Midazolam—Rash—Dactinomycin—skin cancer	0.000386	0.00141	CcSEcCtD
Midazolam—ABCB1—mammalian vulva—skin cancer	0.000386	0.00413	CbGeAlD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000382	0.00139	CcSEcCtD
Midazolam—Hypersensitivity—Fluorouracil—skin cancer	0.000376	0.00137	CcSEcCtD
Midazolam—Dry mouth—Docetaxel—skin cancer	0.000376	0.00137	CcSEcCtD
Midazolam—Confusional state—Docetaxel—skin cancer	0.000372	0.00135	CcSEcCtD
Midazolam—Anaphylactic shock—Docetaxel—skin cancer	0.000369	0.00134	CcSEcCtD
Midazolam—Dizziness—Temozolomide—skin cancer	0.000367	0.00134	CcSEcCtD
Midazolam—Nausea—Dactinomycin—skin cancer	0.000364	0.00133	CcSEcCtD
Midazolam—Shock—Docetaxel—skin cancer	0.000363	0.00132	CcSEcCtD
Midazolam—Nervous system disorder—Docetaxel—skin cancer	0.000362	0.00132	CcSEcCtD
Midazolam—Pruritus—Fluorouracil—skin cancer	0.000361	0.00132	CcSEcCtD
Midazolam—Tachycardia—Docetaxel—skin cancer	0.00036	0.00131	CcSEcCtD
Midazolam—Skin disorder—Docetaxel—skin cancer	0.000358	0.0013	CcSEcCtD
Midazolam—Vomiting—Temozolomide—skin cancer	0.000352	0.00128	CcSEcCtD
Midazolam—Rash—Temozolomide—skin cancer	0.00035	0.00127	CcSEcCtD
Midazolam—Dermatitis—Temozolomide—skin cancer	0.000349	0.00127	CcSEcCtD
Midazolam—Headache—Temozolomide—skin cancer	0.000347	0.00127	CcSEcCtD
Midazolam—Hypotension—Docetaxel—skin cancer	0.000344	0.00126	CcSEcCtD
Midazolam—ABCB1—lymphoid tissue—skin cancer	0.000342	0.00367	CbGeAlD
Midazolam—Dizziness—Fluorouracil—skin cancer	0.000338	0.00123	CcSEcCtD
Midazolam—Paraesthesia—Docetaxel—skin cancer	0.000331	0.00121	CcSEcCtD
Midazolam—ABCB1—female reproductive system—skin cancer	0.00033	0.00354	CbGeAlD
Midazolam—Nausea—Temozolomide—skin cancer	0.000329	0.0012	CcSEcCtD
Midazolam—Dyspnoea—Docetaxel—skin cancer	0.000329	0.0012	CcSEcCtD
Midazolam—Somnolence—Docetaxel—skin cancer	0.000328	0.00119	CcSEcCtD
Midazolam—Vomiting—Fluorouracil—skin cancer	0.000325	0.00118	CcSEcCtD
Midazolam—Dyspepsia—Docetaxel—skin cancer	0.000325	0.00118	CcSEcCtD
Midazolam—Rash—Fluorouracil—skin cancer	0.000322	0.00117	CcSEcCtD
Midazolam—Dermatitis—Fluorouracil—skin cancer	0.000322	0.00117	CcSEcCtD
Midazolam—Headache—Fluorouracil—skin cancer	0.00032	0.00117	CcSEcCtD
Midazolam—Gastrointestinal disorder—Docetaxel—skin cancer	0.000318	0.00116	CcSEcCtD
Midazolam—Fatigue—Docetaxel—skin cancer	0.000318	0.00116	CcSEcCtD
Midazolam—Constipation—Docetaxel—skin cancer	0.000315	0.00115	CcSEcCtD
Midazolam—Pain—Docetaxel—skin cancer	0.000315	0.00115	CcSEcCtD
Midazolam—Feeling abnormal—Docetaxel—skin cancer	0.000304	0.00111	CcSEcCtD
Midazolam—Nausea—Fluorouracil—skin cancer	0.000303	0.00111	CcSEcCtD
Midazolam—ABCB1—head—skin cancer	0.000276	0.00296	CbGeAlD
Midazolam—Hypersensitivity—Docetaxel—skin cancer	0.000272	0.00099	CcSEcCtD
Midazolam—Asthenia—Docetaxel—skin cancer	0.000265	0.000964	CcSEcCtD
Midazolam—Pruritus—Docetaxel—skin cancer	0.000261	0.00095	CcSEcCtD
Midazolam—Dizziness—Docetaxel—skin cancer	0.000244	0.000888	CcSEcCtD
Midazolam—Vomiting—Docetaxel—skin cancer	0.000234	0.000854	CcSEcCtD
Midazolam—Rash—Docetaxel—skin cancer	0.000232	0.000847	CcSEcCtD
Midazolam—Dermatitis—Docetaxel—skin cancer	0.000232	0.000846	CcSEcCtD
Midazolam—Headache—Docetaxel—skin cancer	0.000231	0.000842	CcSEcCtD
Midazolam—Nausea—Docetaxel—skin cancer	0.000219	0.000798	CcSEcCtD
Midazolam—ABCB1—lymph node—skin cancer	0.000193	0.00207	CbGeAlD
